Immunosuppression: Have We Learnt Anything? Immunosuppression: Have We Learnt Anything?
This review looks at the findings from recent clinical trials regarding the use of immunosuppression after lung transplantation.Seminars in Respiratory and Critical Care Medicine
This study not only provides new insights into the nature of lung allografts as a primary site where T and B cell priming and immune regulation can occur, but also introduces the mouse orthotopic lung transplant as a model for studying the immunobiology of AMR. Because AMR can be so difficult to effectively treat in lung transplant recipients, the development of an animal model is a major advance in understanding the immunopathogenesis of AMR.
(Wiley) In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
The researchers have found a way to genetically modify tobacco plants to produce large quantities of collagen almost identical to the body ’s own.
This study evaluates the predictive validity of this instrument.
We report the case of a 51-year-old patient who underwent bilateral lung transplantation and presented with an unstable condition and sepsis 6 days after transplantation. The performed contrast enhanced spectral detector computed tomography (CT) using a dual-layer detector showed absence of perfusion in the left lung on iodine maps, although branches of the pulmonary artery were patent. This prompted retrospective evaluation of CT images and total venous occlusion of the left pulmonary veins was found. Here, iodine maps helped in raising conspicuity of loss of lung perfusion.
ConclusionWith an experienced team, and the proper equipment, on-ECMO air transport of critical patients over thousands of kilometers is today safely feasible.
Authors: Bondeelle L, Bergeron A Abstract INTRODUCTION: Progress in allogeneic hematopoietic stem cell transplantation (HSCT) procedures have been associated with improved survival in HSCT recipients. However, they have also brought to light organ-specific complications, especially pulmonary complications. In this setting, pulmonary complications are consistently associated with poor outcomes, and improved management of these complications is required. Areas covered: We review the multiple infectious and noninfectious lung complications that occur both early and late after allogeneic HSCT. This includes the descrip...